HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases [PDF]
Chonnam Medical Journal, 2016 Histone deacetylases (HDACs) are epigenetic regulators that regulate the histone tail, chromatin conformation, protein-DNA interaction, and even transcription. HDACs are also post-transcriptional modifiers that regulate the protein acetylation implicated in several pathophysiologic states.
Yoon, Somy, Eom, Gwang Hyeon
openaire +2 more sources
Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo [PDF]
, 2013 Targeted drugs have significantly improved the therapeutic options for advanced renal cell carcinoma (RCC). However, resistance often develops, negating the benefit of these agents.
Bartsch, Georg +6 more
core +6 more sources
Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer [PDF]
, 2019 Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is inherently resistant to current treatments, and novel ...
Adile, Ashley A. +19 more
core +3 more sources
Identification of Novel 4-Oxo-4H-chromen-Hydroxamic Acid Derivative Targeting Selected HDAC Isoforms
Archives of Pharmaceutical Sciences Ain Shams University, 2023 Histone deacetylase inhibitors (HDACIs) represent a well-known class of compounds that exhibit potential therapeutic efficacy in a variety of diseases, particularly cancer and neurodegenerative disorders.
Rosaline Ashraf +3 more
doaj +1 more source
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer [PDF]
, 2016 Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer ...
A Hayashi +130 more
core +1 more source
Turning off the switch in medulloblastoma. The inhibitory acetylation of an oncogene [PDF]
, 2010 [No abstract ...
CANETTIERI, Gianluca +4 more
core +1 more source
HDACs and HDAC inhibitors in colon cancer [PDF]
Epigenetics, 2008 The histone deacetylase (HDAC) family of transcriptional co-repressors have emerged as important regulators of colon cell maturation and transformation. Pharmacological inhibitors of class I and II HDAC activity (HDACi) are potent inducers of growth arrest, differentiation and apoptosis of colon cancer cells in vitro and in vivo, implicating a role for
openaire +2 more sources
HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma [PDF]
, 2016 Indexación: Web of ScienceBackground: Class I histone deacetylases (HDACs) have been reported to be overexpressed in clear cell renal cell carcinoma (ccRCC), whereas the expression of class II HDACs is unknown.
Attwood, Kris +14 more
core +2 more sources
Histone deacetylase 2-mediated deacetylation of the Ribonuclease 1 promoter in inflamed human endothelial cells [PDF]
, 2020 Endothelial cells (ECs) function as protective barrier to separate the blood from the surrounding tissue by conducting crucial roles in regulation and maintenance of vascular homeostasis, such as control of vessel permeability or coagulation.
Bedenbender, Katrin
core +1 more source
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]
, 2016 Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S. +17 more
core +2 more sources